Michael A Barry

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Systemic delivery of therapeutic viruses
    Michael A Barry
    Mayo Clinic, Rochester, MN 55902, USA
    Curr Opin Mol Ther 11:411-20. 2009
  2. pmc Advances and future challenges in adenoviral vector pharmacology and targeting
    Reeti Khare
    Virology and Gene Therapy Program, Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA
    Curr Gene Ther 11:241-58. 2011
  3. pmc Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
    Elena V Shashkova
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Virology 394:311-20. 2009
  4. pmc Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus
    Konstantin Doronin
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Hum Gene Ther 20:975-88. 2009
  5. pmc Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer
    Reeti Khare
    Virology and Gene Therapy Program, Mayo Graduate School, Rochester, Minnesota, USA
    Mol Ther 19:1254-62. 2011
  6. pmc Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus
    Elena V Shashkova
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 17:2121-30. 2009
  7. pmc Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV
    Eric A Weaver
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology Program, Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e67574. 2013
  8. pmc Imaging luciferase-expressing viruses
    Michael A Barry
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 797:79-87. 2012
  9. pmc Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy
    Sean E Hofherr
    Division of Infectious Diseases, Department of Internal Medicine, and Translational Immunovirology Program, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 20:169-80. 2009
  10. doi request reprint Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors
    Michael A Barry
    Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 651:227-39. 2010

Collaborators

  • Philip Ng
  • Toshie Sakuma
  • Sumit Middha
  • Guojun Yang
  • Tayaramma Thatava
  • Seiga Ohmine
  • Guido Ferrari
  • Andrew P Byrnes
  • Richard B Kennedy
  • Philip Greipp
  • Kah Whye Peng
  • Konstantin Doronin
  • Roberto B Cattaneo
  • Nathan W Cummins
  • Eric A Weaver
  • Reeti Khare
  • Adam J Guenzel
  • Matthew L Hillestad
  • Catherine M Crosby
  • Sean E Hofherr
  • Christopher Y Chen
  • Elena V Shashkova
  • Lu Kang
  • Mallory A Turner
  • Shannon M May
  • Jason M Tonne
  • Donna Palmer
  • Julien S Senac
  • Karl A Nath
  • Dietrich Matern
  • K Jagannadha Sastry
  • Tien V Nguyen
  • Joseph P Grande
  • Zvonimir S Katusic
  • Anthony J Croatt
  • Yasuhiro Ikeda
  • Miguel Munoz-Gomez
  • Jan P Kraus
  • Yogish C Kudva
  • Richard J Webby
  • Pramod N Nehete
  • Larry R Pease
  • Greg J Heller
  • William E Matchett
  • Christopher A Parks
  • Stephanie S Anguiano-Zarate
  • George T Mercier
  • Gianrico Farrugia
  • Pramod Nehete
  • Moustafa El Khatib
  • Hind J Fadel
  • Zenaido T Camacho
  • Renata Collard
  • Patrick W Hanley
  • Stephanie J Buchl
  • David C Montefiori
  • Sarah Venezia
  • Zhili Xu
  • Eric Weaver
  • Matthew Hillestad
  • Bharti P Nehete
  • Michael C Deeds
  • Vijay S Reddy
  • Glen R Nemerow
  • Kristen E Adams
  • Mathew L Hillestad
  • Diane F Jelinek
  • Nathan Grove
  • Amanda Rosewell
  • Francesco Vetrini
  • Thomas Witzig
  • Adam M Rubrum
  • Shannon May
  • Donna J Palmer
  • Stephanie S Buchl

Detail Information

Publications39

  1. ncbi request reprint Systemic delivery of therapeutic viruses
    Michael A Barry
    Mayo Clinic, Rochester, MN 55902, USA
    Curr Opin Mol Ther 11:411-20. 2009
    ....
  2. pmc Advances and future challenges in adenoviral vector pharmacology and targeting
    Reeti Khare
    Virology and Gene Therapy Program, Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA
    Curr Gene Ther 11:241-58. 2011
    ..Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic effect...
  3. pmc Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
    Elena V Shashkova
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Virology 394:311-20. 2009
    ..Data obtained in this study suggest developing Ad6 and Ad11 as alternative Ads for anticancer treatment...
  4. pmc Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus
    Konstantin Doronin
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Hum Gene Ther 20:975-88. 2009
    ..Shielding adenovirus with 20-kDa PEG may be a useful approach to improve the therapeutic window of oncolytic adenovirus after systemic delivery to primary and metastatic tumor sites...
  5. pmc Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer
    Reeti Khare
    Virology and Gene Therapy Program, Mayo Graduate School, Rochester, Minnesota, USA
    Mol Ther 19:1254-62. 2011
    ..These data suggest that the Ad5/6 hexon-chimera evades Kupffer cells and may have utility for systemic and liver-directed therapies...
  6. pmc Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus
    Elena V Shashkova
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 17:2121-30. 2009
    ..The significantly improved safety of the virus allowed it to be used at increased doses for improved systemic antitumor efficacy. Our results suggest that hexon modifications provide valuable strategies for systemic oncolytic Ad therapy...
  7. pmc Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV
    Eric A Weaver
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology Program, Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 8:e67574. 2013
    ..These data also demonstrate that helper-dependent Ad vaccines can mediate robust vaccine responses in the face of prior immunity to Ad5 and during four rounds of adenovirus vaccination. ..
  8. pmc Imaging luciferase-expressing viruses
    Michael A Barry
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 797:79-87. 2012
    ..Although these methods are simple, the process of obtaining accurate luciferase imaging data has many caveats that are discussed...
  9. pmc Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy
    Sean E Hofherr
    Division of Infectious Diseases, Department of Internal Medicine, and Translational Immunovirology Program, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 20:169-80. 2009
    ..These data show first proof of principle for gene therapy of PA and demonstrate the potential utility of PEG to modify viral tropism in an actual gene therapy application...
  10. doi request reprint Rescue, amplification, purification, and PEGylation of replication defective first-generation adenoviral vectors
    Michael A Barry
    Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 651:227-39. 2010
    ..This chapter details the steps involved when going from recombinant adenoviral vector plasmid all the way to validated PEGylated adenovirus product...
  11. pmc A new model of an arteriovenous fistula in chronic kidney disease in the mouse: beneficial effects of upregulated heme oxygenase-1
    Lu Kang
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Renal Physiol 310:F466-76. 2016
    ....
  12. pmc Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy
    Jason M Tonne
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Dis Model Mech 6:1236-45. 2013
    ..Given the pro-β-cell-survival effects of Cxcl12 (Sdf-1) in inducing GLP-1 production in α-cells, pancreatic GLP-1-mediated Cxcl13 induction might also play a crucial role in maintaining the integrity of β-cells in damaged islets. ..
  13. pmc Circulating antibodies and macrophages as modulators of adenovirus pharmacology
    Reeti Khare
    Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 87:3678-86. 2013
    ..These data suggest a role for IgM-mediated clearance of Ad5 via Kupffer cells and may explain the mechanism by which Ad5/6 evades these cells. These mechanisms may play a vital role in Ad pharmacology in animals and in humans...
  14. pmc Beta cell regeneration after single-round immunological destruction in a mouse model
    Jason M Tonne
    Department of Molecular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA
    Diabetologia 58:313-23. 2015
    ..Here, we employed an adeno-associated virus 8 (AAV8) vector for beta cell-targeted overexpression of a foreign antigen to induce single-round immunological destruction of existing beta cells...
  15. pmc Low seroprevalent species D adenovirus vectors as influenza vaccines
    Eric A Weaver
    Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e73313. 2013
    ..These data support translation of species D adenoviruses as mucosal vaccines and highlight the fundamental effects of differences in virus tropism on vaccine applications. ..
  16. pmc A vector-host system to fingerprint virus tropism
    Matthew L Hillestad
    Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 23:1116-26. 2012
    ..The Cre system therefore provides a unique quantum method to quantify vector delivery that can be applied when vector capacity is limited...
  17. pmc Species D adenoviruses as oncolytics against B-cell cancers
    Christopher Y Chen
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55902, USA
    Clin Cancer Res 17:6712-22. 2011
    ..To determine whether other adenoviruses might have better potency, we "mined" the adenovirus virome of 55 serotypes for viruses that could kill B-cell cancers...
  18. pmc Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model
    Eric A Weaver
    Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Hum Gene Ther 22:1095-100. 2011
    ..These data in immunocompetent mice lend further support to species D Ads as promising oncolytic viruses against B cell cancers...
  19. pmc Induction and functional significance of the heme oxygenase system in pathological shear stress in vivo
    Lu Kang
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota
    Am J Physiol Heart Circ Physiol 308:H1402-13. 2015
    ..Induction of HO-1 may reside in NF-κB activation, and, along with induced HO-2, such upregulation of HO-1 provides a countervailing vasoprotective response in pathological shear stress in vivo. ..
  20. pmc Mucosal vaccination by adenoviruses displaying reovirus sigma 1
    Eric A Weaver
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA
    Virology 482:60-6. 2015
    ..When wereused to immunize mice by the intranasal route, Ad5-R3-sigma produced higher serum and vaginal antibody responses than Ad5. These data suggest optimized Ad-sigma vectors may be useful vectors for mucosal vaccination. ..
  21. ncbi request reprint Mining the adenovirus "virome" for systemic oncolytics
    Michael A Barry
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology Program, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
    Curr Pharm Biotechnol 13:1804-8. 2012
    ..Given this and that there are 54 different serotypes of human Ads, this review considers the utility of "mining" these alternate Ad serotypes for viruses that can evade Ad5 immunity and kill different types of cancer...
  22. pmc Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice
    Nathan W Cummins
    Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    FASEB J 26:2911-8. 2012
    ..HO-1 affects the immune response to both influenza infection and vaccination, suggesting that therapeutic induction of HO-1 expression may represent a novel adjuvant to enhance influenza vaccine effectiveness...
  23. doi request reprint Lentiviral vectors: basic to translational
    Toshie Sakuma
    Department of Molecular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Biochem J 443:603-18. 2012
    ....
  24. pmc Real-time dynamic imaging of virus distribution in vivo
    Sean E Hofherr
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e17076. 2011
    ..These data provide the first in vivo real-time tracking of the rapid initial events of systemic virus infection...
  25. pmc Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses
    Eric A Weaver
    Division of Infectious Diseases, Department of Internal Medicine, and Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA
    Hum Gene Ther 19:1369-82. 2008
    ..These data indicate that PEGylation can enable more effective application of Ad5 and perhaps other Ad serotype vaccines during prime-boost vaccination...
  26. pmc Characterization of species C human adenovirus serotype 6 (Ad6)
    Eric A Weaver
    Division of Infectious Diseases, Department of Internal Medicine, Translational Immunovirology and Biodefense Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Virology 412:19-27. 2011
    ..Comparison of hexon hypervariable regions (HVRs) suggests that the higher transduction by Ad5 and 6 as compared to Ad1 and 2 may be related to differences in charge and length...
  27. pmc Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines
    Eric A Weaver
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology Program, Mayo Clinic, Rochester, MN, USA
    PLoS ONE 4:e5059. 2009
    ....
  28. pmc Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
    Tien V Nguyen
    Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Rochester, Minnesota, USA
    Mol Ther Oncolytics 3:. 2016
    ..These data also indicate that PEGylation may improve Ad6 safety, but that this shielding may reduce oncolytic efficacy after intravenous treatment...
  29. pmc Replicating Single-cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses
    Catherine M Crosby
    Department of Medicine Division of Infectious Diseases, Virology and Gene Therapy Graduate Program, Clinical Translational Sciences Graduate Program, Immunology Graduate Program, Department of Immunology, Department of Molecular Medicine, Mayo Clinic, Rochester, MN Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN
    J Virol . 2016
    ..These data suggest that SC-Ads may be more potent vaccine platforms that conventional RD-Ad vectors and may have utility as "needle-free" mucosal vaccines...
  30. pmc Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia
    Adam J Guenzel
    1 Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55905
    Hum Gene Ther 25:837-43. 2014
    ..These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease...
  31. pmc Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors
    Adam J Guenzel
    1 Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55905
    Hum Gene Ther 26:153-60. 2015
    ..However, tissue-specific loss of expression in females reduces efficacy when compared with males. Whether similar sex-biased AAV effects occur in human gene therapy remains to be determined...
  32. pmc Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing
    Adam J Guenzel
    Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 21:1316-23. 2013
    ..Phenotypic correction was transient with first generation Ad whereas AAV8-mediated long-lasting effects. These data suggest that this PA model may be a useful platform for optimizing systemic intravenous therapies for PA. ..
  33. pmc Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors
    Reeti Khare
    Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 86:2293-301. 2012
    ..These data also demonstrate that this conditional genetic-chemical mutation strategy is a useful tool for investigating the interactions of viruses with host tissues...
  34. pmc Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin
    Eric A Weaver
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 6:e18314. 2011
    ..Notably, 80% of mice challenged with 2009 swine flu isolate A/California/4/09 were protected by HA1-con vaccination. These data show that HA1-con in Ad has potential as a rapid and universal vaccine for H1N1 influenza viruses...
  35. pmc Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells
    Mallory A Turner
    Virology and Gene Therapy Program, Mayo Graduate School, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 89:12401-17. 2015
    ..An understanding of these differences expands the knowledge of alternative Ad species and may inform the selection of related Ads for therapeutic development...
  36. doi request reprint Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus
    Elena V Shashkova
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:5896-904. 2008
    ..These data suggest that detargeting oncolytic Ad from liver macrophages and hepatocytes is an effective strategy to increase the therapeutic window for therapy against disseminated tumor sites...
  37. pmc Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines
    Catherine M Crosby
    Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, Minnesota, USA
    J Virol 89:669-75. 2015
    ..These data suggest that SC-Ad vectors may have utility as mucosal vaccines...
  38. pmc Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari
    Toshie Sakuma
    Department of Molecular Medicine, Mayo Clinic, Guggenheim 18 11c, 200 First Street, SW, Rochester, MN 55905, USA
    J Virol 85:1205-13. 2011
    ..These data support the use of Mus pahari as a model for XMRV pathogenesis and as a platform for vaccine and drug development against this potential human pathogen...
  39. pmc Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
    Roberto Cattaneo
    Department of Molecular Medicine, Rochester, MayoClinic, Minnesota 55905, USA
    Nat Rev Microbiol 6:529-40. 2008
    ..Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation...